Literature DB >> 26254384

Impact of Chemoradiation-induced Myelosuppression on Prognosis of Patients with Locally Advanced Esophageal Cancer After Chemoradiotherapy Followed by Esophagectomy.

Masaichi Ohira1, Naoshi Kubo2, Yoshito Yamashita3, Katsunobu Sakurai1, Takahiro Toyokawa1, Hiroaki Tanaka1, Kazuya Muguruma1, Kosei Hirakawa1.   

Abstract

BACKGROUND: The prognosis of patients with locally advanced esophageal squamous cell carcinoma (LAESC) is extremely poor. The impact of adverse effects of chemoradiotherapy (CRT), particularly myelosuppression, on postoperative long-term results has remained unclear. PATIENTS AND METHODS: A total of 44 patients with LAESC who underwent CRT followed by esophagectomy were enrolled. We compared long-term survival by various clinical variables, including myelosuppression (Grade 3 and 4 leukopenia) due to CRT, response to CRT, performance status, postoperative complications, and pathological nodal status. Finally, multivariate analysis of prognostic factors was assessed by the Cox proportional hazards model.
RESULTS: The mean age of patients was 62.8 years and the male/female ratio was 32/9. The response rate to CRT was 75% (33/44), which included five cases with complete response and 28 cases with partial response. Grade 3 and 4 leukopenia was 43% (19/44). Mortality and postoperative pneumonia occurred in 3 (7.3%) and 14 cases (31.8%), respectively. Multivariate analysis demonstrated that myelosuppression was a significant negative prognostic factor in overall survival (OS) [hazard ratio (HR)=4.758, p=0.005]. The 5-year OS rate was significantly poorer in the group with myelosuppression than in the group without (15.4% vs. 69.0%, p=0.003). Discontinuation of the preoperative CRT schedule and dose reduction of chemotherapeutic agents was significantly more frequent in the group with myelosuppression than in the group without (p=0.003), and peripheral lymphocyte counts after surgery was significantly lower, which may explain poor prognosis in the group with myelosuppression.
CONCLUSION: Pre-operative CRT-induced myelosuppression has a negative impact on the prognosis of patients with LAESC. Our findings indicate that a careful postoperative follow-up is required for patients who develop myelosuppression after neoadjuvant CRT followed by curative resection for locally advanced esophageal cancer. Copyright
© 2015 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.

Entities:  

Keywords:  Esophageal cancer; chemoradiation; myelosuppression

Mesh:

Year:  2015        PMID: 26254384

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  5 in total

1.  Chemotherapy-Induced Myelosuppression in Esophageal Cancer Patients: Risks and Suggestions for Its Management.

Authors:  Qi-Lin Zhang; Ting-Ting Wu; Yong Han; Zi-Ming Zheng; Yu Zhang
Journal:  Curr Med Sci       Date:  2022-06-01

2.  Factors Influencing Compliance to Radical Treatment of Middle Thoracic Esophageal Cancer: An Audit from a Regional Cancer Centre.

Authors:  Rakesh Kapoor; Anshuma Bansal; Shikhar Kumar; Ravi Teja Miriyala
Journal:  Indian J Palliat Care       Date:  2016 Jul-Sep

Review 3.  A Data Mining-Based Analysis of Medication Rules in Treating Bone Marrow Suppression by Kidney-Tonifying Method.

Authors:  Xing You; Yinkun Xu; Jin Huang; Yaofeng Zhi; Fengzhen Wu; Fuping Ding; Jiaying Liang; Zhihui Cui; Jingyan Xu; Jin Zhang
Journal:  Evid Based Complement Alternat Med       Date:  2019-02-03       Impact factor: 2.629

4.  Lymphocyte-Sparing Effect of Proton Therapy in Patients with Esophageal Cancer Treated with Definitive Chemoradiation.

Authors:  Penny Fang; Yutaka Shiraishi; Vivek Verma; Wen Jiang; Juhee Song; Brian P Hobbs; Steven H Lin
Journal:  Int J Part Ther       Date:  2018

5.  Influence of preoperative chemotherapy-induced leukopenia on survival in patients with esophageal squamous cell carcinoma: exploratory analysis of JCOG9907.

Authors:  Hiroki Hara; Junki Mizusawa; Shuichi Hironaka; Ken Kato; Hiroyuki Daiko; Tetsuya Abe; Kenichi Nakamura; Nobutoshi Ando; Yuko Kitagawa
Journal:  Esophagus       Date:  2020-06-08       Impact factor: 4.230

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.